ERBB3 and head and neck squamous cell carcinoma: Thus, based on the properties of the distribution of HRG expression and the biochemical association between HRG expression and pHER3 activity, it seems reasonable to hypothesize that a potential cut-off for identifying patients with SCCHN that might benefit from HER3-directed therapeutic intervention could be defined by comparing HRG expression levels with clinical activity in future clinical studies.